Drugs / suprefact
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02703584 | Mar 2016 → Sep 2018 | infertility disorder | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02487823 Background | Oct 2014 → Nov 2017 | metastatic prostate carcinoma | Institut Paoli-Calmettes | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01636505 Comparator | Sep 2012 → Feb 2013 | — | European Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00823602 Comparator | Mar → Oct 2008 | infertility disorder | Yazd Research & Clinical Center for Infertility | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | suprefact | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00823602 ↗ |
| Known as | Buseralin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02703584 ↗ |
| Action | Activate | “GnRH agonist, suprefact” NCT00823602 ↗ |